Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Technivie Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Technivie (ombitasvir/paritaprevir/ritonavir) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage of Technivie for adults with chronic hepatitis C virus genotype 4 infection, with or without compensated cirrhosis. It specifies initial approval criteria, continuation of an existing course, and conditions that are not approved.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTechnivie Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchived without content revision
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionDocument that the patient meets the FDA-approved indication criteria before requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was archived on January 22, 2019 without a content revision.

    12 weeksCourse duration
    Genotype 4Covered HCV genotype
    18+Minimum age
    ≥ 2Fibrosis threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Child-Pugh B/C
    Not approved

    Coverage Criteria

    FDA-approved indication: chronic HCV genotype 4

    Approve for 12 weeks when all required criteria are met.

    Required criteria

    • Initial therapy requirements: The patient is at least 18 years of age; Technivie is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; and the patient has a fibrosis score of at least 2.Age ≥ 18; fibrosis score ≥ 2
    • Liver disease status: The patient has no cirrhosis; or the patient has compensated cirrhosis (Child-Pugh class A) and Technivie is prescribed in combination with ribavirin.Child-Pugh class A if cirrhosis is present

    Continuation of started therapy

    Approve the remaining duration needed to complete the authorized 12-week course.

    Continuation therapy: The patient has already started Technivie for an indication addressed as approved under the FDA-approved indication criteria, and approval is limited to the duration needed to complete a 12-week course.Complete 12 weeks total

    The remaining duration equals 12 weeks minus the number of weeks already received; for example, 3 weeks received permits approval for 9 additional weeks.

    Technivie is not approved for HCV with Child-Pugh class B or C liver disease, HCV that is not genotype 4, or combination with any other direct-acting antivirals except ribavirin. Coverage is also not approved for patients with life expectancy 12 months due to non-liver-related comorbidities, patients younger than 18 years, or retreatment after prior Viekira Pak or Technivie.

    Clinical Thresholds

    Fibrosis Threshold
    Required fibrosis score≥ 2
    Applies toInitial Technivie authorization for chronic HCV genotype 4
    Authorization contextRequired along with adult age and specialist prescribing or consultation

    Provider Actions

    Documentation Required

    Initial Authorization Criteria

    Coverage of Technivie is recommended for chronic HCV genotype 4 for a 12-week course when all FDA-approved indication criteria are documented. For patients with compensated cirrhosis (Child-Pugh A), Technivie must be prescribed with ribavirin.

    • Patient is 18 years of age or older.
    • Technivie is prescribed by, or in consultation with, a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • The patient has a fibrosis score of ≥ 2.
    • The patient has chronic HCV genotype 4.
    • If the patient has compensated cirrhosis (Child-Pugh A), Technivie is prescribed in combination with ribavirin.
    Denial Risk

    Nonapproved Uses

    Clinical Background

    Technivie, used with ribavirin, is indicated for treatment of chronic HCV genotype 4 infection in adults without cirrhosis or with compensated cirrhosis (Child-Pugh class A). The policy references use in treatment-naive and treatment-experienced patients, including patients with cirrhosis, when prescribed with weight-based ribavirin.

    Clinical Definitions

    Compensated Cirrhosis
    DefinitionCompensated cirrhosis is Child-Pugh class A liver disease
    Approved populationPatients with genotype 4 chronic HCV with compensated cirrhosis may receive Technivie
    Ribavirin requirementTechnivie must be prescribed in combination with ribavirin when compensated cirrhosis is present
    Child-Pugh Class B or C
    DefinitionChild-Pugh class B or C liver disease
    SeverityModerate or severe hepatic impairment
    Coverage status

    Initial Therapy

    Genotype 4 chronic HCV

    Approve Technivie for 12 weeks when all required criteria are met.

    Initial therapy: The patient is at least 18 years old; Technivie is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; the patient has a fibrosis score of at least 2; and, if the patient has compensated cirrhosis (Child-Pugh class A), Technivie is prescribed with ribavirin.Age ≥ 18; fibrosis score ≥ 2; 12 weeks

    The indication is chronic HCV genotype 4 without cirrhosis or with compensated cirrhosis.

    Continuation Therapy

    Complete 12-week course

    Patients already started on Technivie may be approved to complete the authorized course.

    Continuation: The patient started Technivie for an indication addressed as approved in the FDA-approved indication section; authorize only the duration needed to complete a 12-week course.12-week total course

    The remaining duration equals 12 weeks minus the number of weeks already received.

    Quantity Limits

    Technivie Quantity Limit
    Authorized quantity12 weeks per course
    Initial therapyApprove for 12 weeks when all required criteria are met
    Continuation therapyAuthorize only the remaining duration needed to complete the 12-week course
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTechnivie Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchived without content revision
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionDocument that the patient meets the FDA-approved indication criteria before requesting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsProvider ActionsClinical BackgroundClinical DefinitionsInitial TherapyContinuation TherapyQuantity Limits

    Requests for patients already started on Technivie may be approved only to complete the authorized 12-week course for an indication covered under the FDA-approved criteria. Technivie is not approved for the following conditions or combinations.

    • For an eligible patient already receiving Technivie, approve only the remaining duration needed to complete a 12-week course.
    • Do not approve for HCV with Child-Pugh class B or C liver disease (moderate or severe hepatic impairment).
    • Do not approve for HCV that is non-genotype 4.
    • Do not approve Technivie in combination with any other direct-acting antivirals (DAAs), except ribavirin.
    • Do not approve when life expectancy is less than 12 months due to non-liver-related comorbidities.
    • Do not approve for pediatric patients younger than 18 years.
    • Do not approve retreatment with Technivie in patients previously treated with Viekira Pak (paritaprevir/ritonavir/ombitasvir plus dasabuvir) or Technivie.
    Not an approved use of Technivie under this policy